Pharmacokinetics of teduglutide in subjects with renal impairment

What Was Tested

This controlled clinical trial paper looks at Teduglutide (GLP-2 analog).

Teduglutide is a recombinant analogue of human glucagon-like peptide-2 that has recently been approved for the treatment of short bowel syndrome in adults.

Who Took Part

According to the abstract, 6 subjects were involved.

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

This was an open-label study with six parallel groups (6 subjects each).

Three groups with renal impairment (moderate, severe and end-stage renal disease) were compared to healthy subjects with normal renal function, which were matched to the renal-impaired subjects with respect to demographics.

How the Study Was Run

The design is described as open-label and parallel-group.

Everyone knew when Teduglutide (GLP-2 analog) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The Teduglutide (GLP-2 analog) group and the comparison group ran side by side rather than switching.

At least two elderly subjects (≥65 years) were enrolled per group.

What Was Measured

Topics PubMed links to this paper include Age Factors, Kidney Failure, Chronic, Peptides and Renal Insufficiency.

What This Means in Plain Language

The paper is an open-label and parallel-group study of Teduglutide (GLP-2 analog) in 6 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (European journal of clinical pharmacology), a journal based in Germany.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.